2019 Chemotherapy Pharmaceutical Companies 
Drug Topics
AUGUST 12, 2025
First, a pharmaceutical company could submit an investigational new drug (IND) application for a product with fixed concentrations of cannabinoids to the FDA for approval. Updated November 2019. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. There are 2 likely tracks. 4 Following 21 CFR § 1306.26
pharmaphorum
JULY 18, 2025
Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 25, 2023
Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, and the findings raise questions about the extent to which industry influence may have led to patient harm, according to a new study.
pharmaphorum
JUNE 8, 2021
At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6%
European Pharmaceutical Review
DECEMBER 12, 2023
Pharmaceutical companies such as Sanofi and AstraZeneca are currently conducting several high-potential clinical development programmes in oncology in collaboration with Innate Pharma. Innate Pharma has also partnered with Takeda to develop an antibody drug conjugate (ADC). percent, reaching even 57.1 percent in the skin.
pharmaphorum
JULY 1, 2025
billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal. billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal. billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal.
Hospital Pharmacy Europe
AUGUST 17, 2023
GoCART aims to promote patient access to novel cellular therapies, bringing together different stakeholders, including healthcare professionals, health authorities, pharmaceutical companies, patient representatives, health technology assessment bodies, reimbursement agencies and medical non-profit organisations.
Expert insights. Personalized for you.
Let's personalize your content